Company intelligence
Nephrogen
Curative genetic medicines for kidney and pancreatic diseases
Biotechnology Research
New York, US
6 employees
Founded 2022
1 public signals
About Nephrogen
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas.
Verified activity
Signals from Nephrogen
1 published signal